Prime Medicine, Inc. PRME
3.84 USD -0.35 (-8.35%)
Regular-session close
3.92 +0.08 +1.96%
After hours · Nov 17, 7:50 PM ET
3.82 Day range 4.41
2.67 52-week range 5.91
- YTD
- +10.66%
- 1 year
- +0.52%
News
benzinga.com HC Wainwright & Co. Reiterates Buy on Prime Medicine, Maintains $8 Price Target HC Wainwright & Co. analyst Arthur He reiterates Prime Medicine (NASDAQ:PRME) with a Buy and maintains $8 price target.
zacks.com Prime Medicine, Inc. (PRME) Reports Q3 Loss, Lags Revenue Estimates Prime Medicine, Inc. (PRME) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to a loss of $0.32 per share a year ago.benzinga.com Prime Medicine Q3 EPS $(0.22) Beats $(0.25) Estimate, Sales $4.213M Beat $1.206M Estimate Prime Medicine (NASDAQ:PRME) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.25) by 12 percent. This is a 31.25 percent increase over losses of $(0.32)…
globenewswire.com Prime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares CAMBRIDGE, Mass., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic…
globenewswire.com Prime Medicine Reports Third Quarter 2026 Financial Results and Provides Business Updates -- First patient dosed in global Phase 1/2 clinical trial of PM577a in Wilson disease, the first clinical study of an in vivo Prime Editing therapy from Prime Medicine; initial clinical data expected…
247wallst.com Cathie Wood Dumps the Last of Teradyne From Her Flagship Fund ARK's flagship fund exited a chip-testing stock just as it surged on a fresh Buy rating, and Wood offered no explanation. Another ARK fund still holds millions in shares, so the real question is what…
globenewswire.com Prime Medicine Announces Pricing of Public Offering of Common Stock CAMBRIDGE, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic…benzinga.com Prime Medicine Commences $125M Offering Of Common Shares Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that it has commenced an…
globenewswire.com Prime Medicine Announces Proposed $125.0 Million Public Offering of Common Stock CAMBRIDGE, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic…
